IV期黑色素瘤患者转移性疾病切除后接受肽疫苗治疗的生存分析。
Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma.
作者信息
Tagawa Scott T, Cheung Eric, Banta Warren, Gee Conway, Weber Jeffrey S
机构信息
Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
出版信息
Cancer. 2006 Mar 15;106(6):1353-7. doi: 10.1002/cncr.21748.
BACKGROUND
Metastatic melanoma carries a poor prognosis, with a median survival of 7-9 months. Surgical resection of metastatic disease has been advocated to improve survival. Immunotherapy after metastasectomy may further improve the outcome for high-risk resected disease.
METHODS
Charts from patients treated on institutional vaccine trials were analyzed. Patients with American Joint Committee on Cancer (AJCC) Stage IV melanoma who underwent surgical resection of metastatic sites followed by treatment on a peptide vaccine trial were eligible for this study. Survival was calculated from the date of enrollment on the clinical trial.
RESULTS
Forty-one patients met inclusion criteria. The median age was 56.5 years, with approximately equal numbers of men and women. The ECOG performance status was 0 in all patients. Approximately 46% of patients underwent resection of visceral metastases before vaccine. The median follow-up was 5.6 years. The median overall survival was 3.8 years.
CONCLUSIONS
In selected patients with AJCC Stage IV melanoma, resection of metastatic disease followed by vaccine therapy can result in long-term survival.
背景
转移性黑色素瘤预后较差，中位生存期为7 - 9个月。提倡对转移性疾病进行手术切除以提高生存率。转移灶切除术后进行免疫治疗可能会进一步改善高危切除疾病的预后。
方法
分析了在机构疫苗试验中接受治疗的患者的病历。符合美国癌症联合委员会（AJCC）IV期黑色素瘤且接受转移部位手术切除并随后参加肽疫苗试验治疗的患者符合本研究条件。从临床试验入组日期开始计算生存期。
结果
41名患者符合纳入标准。中位年龄为56.5岁，男女数量大致相等。所有患者的东部肿瘤协作组（ECOG）体能状态均为0。约46%的患者在接种疫苗前接受了内脏转移灶切除。中位随访时间为5.6年。中位总生存期为3.8年。
结论
在选定的AJCC IV期黑色素瘤患者中，切除转移性疾病后进行疫苗治疗可实现长期生存。
Zotero 插件